Point Biopharma Global Inc (PNT) Return on Equity ROE from the third quarter 2023 to third quarter 2022 and annually, average high and low, overall ranking from Sep 30 2023 to Sep 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Point Biopharma Global Inc   (NASDAQ: PNT)

Point Biopharma Global Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Point Biopharma Global Inc in the third quarter 2023?
Point Biopharma Global Inc achieved a return on average equity (ROE) of 21.1 % in its third quarter 2023, this is above PNT's average return on equity of -1.43%.
Point Biopharma Global Inc shareholder's equity over the 12 months ending in its third quarter 2023 are valued at $458 million

ROE fell compared to the second quarter 2023, despite the net income growth of % from the second quarter 2023.

Within the Major Pharmaceutical Preparations industry 24 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2023 from 600 to 615.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter
Y / Y Equity Change 37.24 % 107.75 % 97.17 % 90.8 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions 97 97 98 98 -79
Return On Equity (TTM) 21.1 % 22.69 % 26.47 % 31.44 % -31.08 %
PNT's Total Ranking # 615 # 600 # 435 # 367 # 0
Equity (TTM) in Millions 424 447 472 487 309
Seq. Equity Change -5.2 % -5.16 % -3.12 % 57.55 % 43.5 %
Seq. Net Income Change - - - - -

Back to PNT Management Effectiveness >> PNT's 5 Years Annual ROE >> Compare PNT ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 25
Sector # 63
Overall # 615

Return On Equity Statistics
High Average Low
31.44 %
-1.43 %
-31.08 %
(Dec 31 2022)   (Sep 30 2022)





PNT Annual Return On Equity (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020

Total Equity in Millions 487 255 5 0 0
Y / Y Equity Change 90.8 % 5004.25 % - - -
Net Income in Millions 98 -46 0 0 0
Y / Y Net Income Change - - - - -
Return On Equity 20.19 % -17.99 % -6.23 % - -

Back to PNT Management Effectiveness >> PNT's 5 Years Annual ROE >> Compare PNT ROE to its Competitors




Annual Roe Comment
In 2022 ROE improved to 20.19 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PNT's' Return on Equity at Yahoo Finance
PNT's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PNT's Competitors
Subscribers only: Roe for Point Biopharma Global Inc 's Suppliers
Subscribers only: Return On Equity for PNT's Customers




Companies with similar Return On Equity at Sep 30 2023, within Healthcare Sector ROE
Cv Sciences Inc   56.96 %
Elite Pharmaceuticals Inc   55.08 %
Omeros Corporation  54.32 %
Vaso Corporation  50.49 %
Zoetis Inc   49.00 %
Enzo Biochem Inc  47.55 %
Star Equity Holdings Inc   47.18 %
Abbvie Inc   46.90 %
Johnson and Johnson  46.90 %
Eli Lilly And Company  44.81 %
Zymeworks Inc   44.62 %
Escalon Medical Corp   42.84 %
Entera Bio Ltd   42.52 %
Tenet Healthcare Corp  42.44 %
Shockwave Medical Inc   42.41 %
Nrc Health  40.74 %
Baxter International Inc   40.60 %
Viskase Holdings inc   35.29 %
Tao Synergies Inc   34.96 %
Arcturus Therapeutics Holdings Inc   34.11 %
Harmony Biosciences Holdings inc   33.27 %
Macrogenics Inc   32.31 %
Voyager Therapeutics Inc   32.13 %
Semler Scientific inc   30.96 %
Denali Therapeutics Inc   30.61 %
Agilent Technologies inc   30.40 %
Gilead Sciences Inc   27.28 %
Exicure Inc   27.15 %
Bruker Corporation  26.84 %
Chemed Corporation  26.80 %

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.